Torii Pharmaceutical Co Ltd
TSE:4551
Torii Pharmaceutical Co Ltd
Change in Working Capital
Torii Pharmaceutical Co Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
Change in Working Capital
-¥3.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Change in Working Capital
-¥234.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-8%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Change in Working Capital
-¥324.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Change in Working Capital
-¥169.3B
|
CAGR 3-Years
-172%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
1%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Change in Working Capital
-¥130.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
-14%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Change in Working Capital
-¥209.9B
|
CAGR 3-Years
-105%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
See Also
What is Torii Pharmaceutical Co Ltd's Change in Working Capital?
Change in Working Capital
-3.5B
JPY
Based on the financial report for Dec 31, 2024, Torii Pharmaceutical Co Ltd's Change in Working Capital amounts to -3.5B JPY.
What is Torii Pharmaceutical Co Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
7%
Over the last year, the Change in Working Capital growth was 60%. The average annual Change in Working Capital growth rates for Torii Pharmaceutical Co Ltd have been 12% over the past three years , and 7% over the past ten years .
You don't have any saved screeners yet